MentionFox
Home › Stakes › Stoke Therapeutics, Inc.
5%+ stakes · Schedule 13D and 13G

Stoke Therapeutics, Inc.: 5%+ holders

Who has reported owning 5% or more of Stoke Therapeutics, Inc., from Schedule 13D and 13G filings: each holder's stake as filed, the timeline, and the purpose each 13D states, quoted.

At 5% or more7
Filings21
Latest filing2026-08-14

Stoke Therapeutics, Inc. has 21 Schedule 13D or 13G filings on record since 2025-07-15. 7 holders' latest filing reports 5% or more of common stock, $0.0001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

HolderPercentSharesLatestEvent date
RTW Investments, LP9.9%5,940,866SCHEDULE 13G/A, 2026-05-152026-03-31
Fmr LLC8.5%5,313,100SCHEDULE 13G/A, 2026-08-062026-06-30
BlackRock, Inc.6.8%3,732,540SCHEDULE 13G/A, 2025-10-172025-09-30
Redmile Group, LLC6.7%4,164,120SCHEDULE 13G/A, 2026-05-152026-03-31
Lynx1 Capital Management LP6.5%4,038,404SCHEDULE 13G/A, 2026-08-142026-06-30
Baker Bros. Advisors LP5.8%3,336,697SCHEDULE 13G/A, 2026-02-172025-12-31
Wellington Management Group LLP5.2%3,095,700SCHEDULE 13G, 2026-05-152026-03-31
The Toronto-Dominion Bank4.9%3,173,258SCHEDULE 13G/A, 2026-08-122026-06-30
BlackRock Portfolio Management LLC4.7%2,550,341SCHEDULE 13G/A, 2025-07-152025-06-30
Skorpios Trust4.1%2,256,181SCHEDULE 13D/A, 2025-08-262025-08-22
Cowen Financial Products LLC0%0SCHEDULE 13G/A, 2025-11-142025-09-30
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-272026-03-13

Purpose of Transaction (Item 4)

Skorpios Trust

Item 4 is hereby amended and supplemented by adding the following: On August 22, 2025, Blue Horizon sold 1,000,000 Shares of the Issuer in an open market transaction at a price of $18.50 per share.Item 4 of the SCHEDULE 13D/A filed 2025-08-26

Timeline

FiledHolderPercentFiling
2025-07-15BlackRock Portfolio Management LLC4.7%SCHEDULE 13G/A
2025-07-29Cowen Financial Products LLC5.8%SCHEDULE 13G/A
2025-08-06Fmr LLC13.6%SCHEDULE 13G/A
2025-08-14Redmile Group, LLC8%SCHEDULE 13G/A
2025-08-26Skorpios Trust4.1%SCHEDULE 13D/A
2025-10-17BlackRock, Inc.6.8%SCHEDULE 13G/A
2025-11-05Fmr LLC12.5%SCHEDULE 13G/A
2025-11-14The Toronto-Dominion Bank5.8%SCHEDULE 13G
2025-11-14Cowen Financial Products LLC0%SCHEDULE 13G/A
2026-02-05Fmr LLC9.8%SCHEDULE 13G/A
2026-02-17Baker Bros. Advisors LP5.8%SCHEDULE 13G/A
2026-03-27The Vanguard Group0%SCHEDULE 13G/A
2026-05-15Wellington Management Group LLP5.2%SCHEDULE 13G
2026-05-15Lynx1 Capital Management LP7%SCHEDULE 13G/A
2026-05-15The Toronto-Dominion Bank5.4%SCHEDULE 13G/A
2026-05-15Redmile Group, LLC6.7%SCHEDULE 13G/A
2026-05-15RTW Investments, LP9.9%SCHEDULE 13G/A
2026-05-18Lynx1 Capital Management LP8.1%SCHEDULE 13G/A
2026-08-06Fmr LLC8.5%SCHEDULE 13G/A
2026-08-12The Toronto-Dominion Bank4.9%SCHEDULE 13G/A
2026-08-14Lynx1 Capital Management LP6.5%SCHEDULE 13G/A

Tools for this story

Each opens in a new tab, filled in for Stoke Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

Cite this page

Permanent URL: https://mentionfox.com/stakes/stoke-therapeutics
Last updated 2026-09-27
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
Stoke Therapeutics, Inc. 5%+ holders: 7 at 5% or more, largest RTW Investments, LP 9.9%. MentionFox, 2026-09-27. https://mentionfox.com/stakes/stoke-therapeutics